The stock of Royalty Pharma plc (NASDAQ: RPRX) has decreased by -1.82 when compared to last closing price of 27.52.Despite this, the company has seen a loss of -2.17% in its stock price over the last five trading days. Seeking Alpha reported 2023-11-08 that Royalty Pharma PLC (NASDAQ:RPRX ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants George Grofik – SVP & Head, IR & Communications Pablo Legorreta – Founder, Chairman & CEO Christopher Hite – Vice Chairman & EVP Terrance Coyne – EVP & CFO Marshall Urist – EVP & Head, Research & Investments Conference Call Participants Christopher Schott – JPMorgan Chase & Co. Stephen Scala – TD Cowen Andrew Baum – Citigroup Michael DiFiore – Evercore ISI Chris Shibutani – Goldman Sachs Group Operator Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Third Quarter 2023 Earnings Conference Call.
Is It Worth Investing in Royalty Pharma plc (NASDAQ: RPRX) Right Now?
The price-to-earnings ratio for Royalty Pharma plc (NASDAQ: RPRX) is above average at 67.52x, while the 36-month beta value is 0.43.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The average price point forecasted by analysts for Royalty Pharma plc (RPRX) is $47.88, which is $21.36 above the current market price. The public float for RPRX is 380.14M, and currently, short sellers hold a 2.89% ratio of that floaft. The average trading volume of RPRX on November 16, 2023 was 2.21M shares.
RPRX’s Market Performance
The stock of Royalty Pharma plc (RPRX) has seen a -2.17% decrease in the past week, with a -5.13% drop in the past month, and a -7.69% fall in the past quarter. The volatility ratio for the week is 2.72%, and the volatility levels for the past 30 days are at 2.53% for RPRX. The simple moving average for the last 20 days is -1.28% for RPRX’s stock, with a simple moving average of -15.65% for the last 200 days.
Analysts’ Opinion of RPRX
Many brokerage firms have already submitted their reports for RPRX stocks, with UBS repeating the rating for RPRX by listing it as a “Buy.” The predicted price for RPRX in the upcoming period, according to UBS is $47 based on the research report published on June 14, 2022 of the previous year 2022.
RPRX Trading at -1.68% from the 50-Day Moving Average
After a stumble in the market that brought RPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.24% of loss for the given period.
Volatility was left at 2.53%, however, over the last 30 days, the volatility rate increased by 2.72%, as shares sank -1.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.05% lower at present.
During the last 5 trading sessions, RPRX fell by -2.17%, which changed the moving average for the period of 200-days by -31.05% in comparison to the 20-day moving average, which settled at $27.35. In addition, Royalty Pharma plc saw -31.63% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at RPRX starting from Coyne Terrance P., who sale 37,500 shares at the price of $30.75 back on Aug 10. After this action, Coyne Terrance P. now owns 790,000 shares of Royalty Pharma plc, valued at $1,153,091 using the latest closing price.
Coyne Terrance P., the EVP & CFO of Royalty Pharma plc, sale 37,500 shares at $30.72 during a trade that took place back on Aug 09, which means that Coyne Terrance P. is holding 827,500 shares at $1,151,936 based on the most recent closing price.
Stock Fundamentals for RPRX
Equity return is now at value 3.00, with 1.10 for asset returns.
In a nutshell, Royalty Pharma plc (RPRX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.